Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
LIN BIOSCIENCE, INC.	6696	Taipei Exchange	215,783	90.7 TWD	Stock
ME LIN STEEL	MEL	HANOI S.E.	535	7,300 VND	Stock
LIN HORN TECHNOLOGY CO., LTD.	5464	Taipei Exchange	168,662	33 TWD	Stock
CHEN LIN EDUCATION GROUP HOLDINGS LIMITED	1593	Hong Kong S.E.	423,571	1.49 HKD	Stock
JIH LIN TECHNOLOGY CO., LTD.	5285	Taiwan S.E.	170,175	70.1 TWD	Stock
ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX J. K. WEBER INVESTMENT		Börse Stuttgart	-	155.3 EUR	Certificat
A. K. CA 9.3/APR27		Bombay S.E.	-	- %	Bond
A. K. CA 9.3/APR27		Bombay S.E.	-	- %	Bond
A. K. CA 8.0/MAY24		Bombay S.E.	-	- %	Bond
SG EFF. CALL24 LIN		Boerse Frankfurt Warrants	-	- PTS	Warrant

See all

News (758)

Monster Beverage Corporation Commences Modified Dutch Auction Tender Offer to Purchase Up to $3.0 Billion of Its Outstanding Common Stock	08/05	AQ
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision	08/05	BU
TELES Informationstechnologien : Annual Financial Statements 2023	30/04	PU
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations	26/04	PU
Transcript : American Electric Power Company, Inc. - Shareholder/Analyst Call	23/04
Bp : simplifies organisational structure and announces executive team changes - Form 6-K	18/04	PU
Annual General Meeting elects Annette Heimlicher as a new member of the Board of Directors and approves all other proposals	18/04	EQ
AstraZeneca : Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Form 6-K	02/04	PU
JBS S A : MANAGEMENT’S PROPOSAL FOR THE ANNUAL AND EXTRAORDINARY SHAREHOLDERS’ MEETING TO BE HELD ON APRIL 26, 2024 - Form 6-K	29/03	PU
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	28/03	AQ
Globe Life : 2024 Proxy and Shareholder Meeting	15/03	PU
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation	13/03	BU
Huber+Suhner : Compensation Report 2023	05/03	PU
Annette Heimlicher stands for election to the Board of Directors of Komax Holding AG	28/02	EQ
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	13/02	GL
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	13/02	AQ
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization	19/01	BU
Arcadium Lithium plc completed the acquisition of Allkem Limited (ASX : AKE) in a merger of equals transaction.	04/01	CI
TELES Informationstechnologien : Annual Financial Statements 2022	27/12	PU
Fubon Financial : FHC Financial Statements(Consolidated) 2023 Q3	27/12	PU
Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer	21/12	PU
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease	15/12	GL
Transcript : SL Green Realty Corp. - Analyst/Investor Day	04/12
AstraZeneca : Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer - Form 6-K	17/11	PU
Bristol Myers Squibb - U.S. Food and Drug Administration Approves Augtyro, a Next-Generation Tyrosine Kinase Inhibitor, for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer	16/11	AQ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)	16/11	BU
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial	09/11	BU
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients	02/11	BU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	23/23/23	PU
Johnson & Johnson : New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC	21/23/21	PU
BridgeBio Pharma : BBIO – KRAS Cancers – 2023 AACR-NCI-EORTC – GTP in Active-state KRASG12C Inhibitors	03/23/03	PU
Johnson & Johnson : Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	28/23/28	PU
PetroChina : 2023 INTERIM REPORT PETROCHINA COMPANY LIMITED - Form 6-K	21/23/21	PU
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®	19/23/19	BU
GBT Technologies : A qualitative study that explores the implementation of artificial intelligence in integrated circuit design - Form 8-K	28/23/28	PU
TeraWulf Announces 7.9 EH/s Expansion Plan and Associated Purchase of 18,500 S19j XP Bitcoin Miners from BITMAIN	18/23/18	GL
Fubon Financial : FHC Financial Statements(Consolidated) 2023 Q1	30/23/30	PU
OPKO HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	24/23/24	AQ
Caledonia Investments : Proxy Form 2023 AGM	15/23/15	PU
© 2023 Tonix Pharmaceuticals Holding Corp. © 2023 Tonix Pharmaceuticals Holding Corp. TNX - 1700 Gastric and Colorectal Cancers NASDAQ: TNXP Version P0451 June 13 , 2023 (Doc 1243) - Form 8-K	14/23/14	PU
BIOMERICA : InFoods - Jun 2023 General Investor	12/23/12	PU
Oatly : PORTIONS OF INFORMATION CONTAINED IN THIS AGREEMENT HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL - Form 6-K	01/23/01	PU
Bollore : Non-financial performance (Chapter 2/URD 2022 Bolloré)	12/23/12	PU
Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023	11/23/11	BU
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy	10/23/10	PR

1234NextSee all

Companies (283)

ALIMENTATION COUCHE-TARD INC. 56 366 M $

Alimentation Couche-Tard Inc. is engaged in convenience and mobility, operating in about 29 countries and territories, with more than 16,700 stores, of which almost 13,100 offer road transportation fuel. With its Couche-Tard and Circle K banners, the Comp ...

ARTHUR J. GALLAGHER & CO. 54 264 M $

Arthur J. Gallagher & Co. specializes in insurance brokerage services. The group also develops risk management activity. Revenues break down by activity as follows: - insurance and reinsurance brokerage services (85.7%); - risk management and assessment ...

PATEL ENGINEERING LIMITED 603 M $

Patel Engineering Limited is an India-based company, which is engaged in civil engineering and construction of hydro projects, dams, tunnels, roads, railways. It is also involved in real estate activities with owned or leased property. Its power, dams and ...

J&T GLOBAL EXPRESS LIMITED 9 420 M $

J&T Global Express Ltd is a China-based company principally engaged in global logistics services. The Company's businesses include express delivery services, cross-border logistics services, sales accessories and other services. The express delivery servi ...

KESKO OYJ 7 398 M $

Kesko Oyj is the leading wholesaler and retailer in Finland. Net sales break down by family of products as follows: - grocery and convenience goods (53.8%; K-retailer; No. 2 in Finland): owned 1,208 supermarkets and stores under the names K-citymarket, K ...

NEW ORIENTAL EDUCATION & TECHNOLOGY GROUP INC. 13 469 M $

New Oriental Education & Technology Group Inc is a China-based company mainly engaged in delivering comprehensive educational programs, services and products to students through its nationwide physical network of schools, learning centers and bookstores, ...

DUBAI ELECTRICITY AND WATER AUTHORITY 30 898 M $

Dubai Electricity and Water Authority PJSC is a United Arab Emirates-based utility services provider. The Company distributes electricity and water and serves residential and commercial customers in the United Arab Emirates. The principal activities of th ...

RECKITT BENCKISER GROUP PLC 39 343 M $

Reckitt Benckiser Group plc specializes in the production and marketing of household cleaning products. The group also produces and sells personal care products and OTC remedies. Net sales break down by product family as follows: - OTC and health product ...

SEKTKELLEREI J.OPPMANN AG 6 M $

Sektkellerei J Oppmann AG is a Germany-based company, which is engaged in the production and distribution of sparkling wine. The Company offers sparking wine from six categories: Distinctively Unique - Traditional Fermentation in the Bottle, which compris ...

YASH CHEMEX LIMITED 7 M $

Yash Chemex Limited is an India-based company that offers fine and specialist chemicals used in various industries. The Company is engaged in the business of manufacturing and selling various types of Chemicals, Dyes, and Intermediates. The Company operat ...

1234Next

Insiders

J. K. Lin

J. K. Lin is SVP-Information Technology & Materials Management at Taiwan Semiconductor Manufacturing Co., Ltd. J. K. Lin received an undergraduate degree from National Changhua University of Education.

J.
K.
Somani formerly worked at Hindustan Sanitaryware & Industries Ltd., as Senior Vice President-Accounts from 1977 to 2010 and AGI Greenpac Ltd., as Senior Vice President from 1977 to 2015.

K. J. Rao

J. K. Gururajan

No results for this search